RenovoRx, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from RenovoRx, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-104.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 83% of Healthcare companies in United States.
Cash Cushion Ratio
+12%Cash, after subtracting all debt, equals 12% of its market value (net cash).
Higher than 53% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
RenovoRx, Inc. made a loss over the last year. RenovoRx, Inc. owes $0.22 for every $1 it owns. RenovoRx, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossRenovoRx, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
6.38The share price is 6.38 times RenovoRx, Inc.'s book value per share, higher than 77% of Healthcare companies in United States.
Market cap
$57 MThe total market value of all of RenovoRx, Inc.'s shares at today's price (share price × number of shares), smaller than 72% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$9 MWhat RenovoRx, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.20Net worth divided by the number of shares. The share price of $1.27 is 6.4 times this, which is the P/B above.
Return on equity (ROE)
-125.2%RenovoRx, Inc. lost 125.2% of its shareholders' money over the last year, lower than 77% of Healthcare companies in United States.
Owes vs Owns
0.22×RenovoRx, Inc. owes $0.22 for every $1 it owns (low), lower than 70% of Healthcare companies in United States.
Dividend yield
NoneRenovoRx, Inc. does not currently pay a dividend.
Revenue growth
+2512%Revenue rose 2512% in the year to Dec 2025.
Profit growth
LossRenovoRx, Inc. made a loss in each of the last two years.
Profit margin
-994.5%RenovoRx, Inc. lost $994 for every $100 of revenue.
Cash vs debt
Net cashRenovoRx, Inc. held $7 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For RenovoRx, Inc.: $57 M ÷ $9 M (30 Jun 2026) = 6.4.
What is RenovoRx, Inc.'s return on equity?
RenovoRx, Inc. lost 125.2% of its shareholders' money over the last year, lower than 77% of Healthcare companies in United States.
How much does RenovoRx, Inc. owe compared with what it owns?
RenovoRx, Inc. owes $0.22 for every $1 it owns (low), lower than 70% of Healthcare companies in United States.
Does RenovoRx, Inc. pay a dividend?
No. RenovoRx, Inc. does not currently pay a dividend.
Is RenovoRx, Inc.'s revenue growing?
Revenue rose 2512% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.